Ari Melnick, MD, is Gebroe Family Professor of Hematology/Oncology in the Departments of Medicine and Pharmacology at the Weill Cornell Medical College in New York City. He is Chair of the Hematologic Malignancies Program of the Weill Cornell Cancer Center and Director of the Sackler Center for Biomedical and Physical Sciences at Weill Cornell.
Dr Melnick’s research interests involve discovering transcriptional and epigenomic mechanisms that drive lymphoid and myeloid neoplasms, and harnessing these mechanisms for development of novel drugs and therapeutic regimens for cancer patients. He has authored or co-authored over 250 papers in journals such as Nature, Science, Cell, Cancer Cell, Nature Medicine and Nature Immunology. Alongside this work, Dr Melnick is passionate about sharing his knowledge in hematology and epigenetics and has chaired many international meetings.
He grew up in Argentina and received his medical degree at the University of Buenos Aires in 1990. Dr Melnick then pursued clinical training, first in the Internal Medicine Residency Program, and then in Hematology and Oncology at Mount Sinai. He then did a post-doctoral fellowship at Mount Sinai in the area of transcriptional regulation in leukemias, and a visiting post-doctoral fellowship at the Memorial Sloan Kettering Cancer Center in the transcriptional regulation of chromatin.